WuXi Biologics breaks ground on CRDMO Center in Singapore
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
The facility will manufacture tablets, capsules, and injections for the oncology segment
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
WINREVAIR is a breakthrough biologic for this rare, progressive disease
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Combination shows consistent benefit across prespecified post-progression outcomes
Subscribe To Our Newsletter & Stay Updated